CAR-T Meeting 2022 | Future perspectives in CAR-T therapy
Michael Loschi, MD, PhD, University Hospital of Nice, Cote d’Azur University, Nice, France, outlines recent developments in the field of chimeric antigen receptor T-cell (CAR-T) therapy. Despite the efficacy of CAR-Ts, many patients still relapse. Therefore, there have been efforts to improve our understanding of the biology of CAR-Ts and ameliorate their design, with advances in dual-targeting CAR-Ts for example. Dr Loschi also talks on CAR-transduced natural killer (NK) cells and allogeneic CAR-Ts, and highlights advances in CAR-Ts in new indications such as multiple myeloma, chronic lymphocytic leukemia (CLL), and T-cell malignancies, which are tumors with substantial unmet clinical needs. Moving forward, Dr Loschi comments on European CAR-T initiatives such as the CARAMBA project. Finally, he mentions remarkable advances in the development of CAR-Ts for solid tumors and interesting studies on the development of immunomodulation following CAR-T therapy. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
